Core 2: Glioblastoma Biorepository Core

PROJECT SUMMARY – CORE 2 The goals of the Glioblastoma Biorepository Core (Core 2) are to provide all P01 members with centralized access to professional banking of samples, patient derived models (PDX/cell lines), neuropathology services and expertise. This includes access to human tumors derived from rQNestin clinical trial patients as well as newly created human and mouse cell lines and xenografts critical to all experimental Project aims. The presence of the Core ensures that all resources are clinically and molecularly annotated with respect to relevant parameters with the goal to aid study and development of oncolytic virus and study of immunotherapy approaches. These resources will specifically aid the projects in their studies of oncolytic virus biology, immunology, and therapeutics in a manner not possible though individual project (e.g. R01) funding mechanisms or through existing cores at each of the P01 institutions. Moreover, by interacting with multiple projects and investigators, the Core will continue to act as a resource that drives collaboration and sharing of the pathological results and findings across the P01. Core 2 has 3 Specific Aims to accomplish its goals. Aim 1: To generate and maintain a repository of consented glioblastoma samples and data. (all Projects) which includes critical samples and pre- post-rQNestin trial patient samples and models for study. Aim 2: To create and distribute glioblastoma patient derived cell lines (PDCL) and xenografts (PDX) (all Projects) which will be used to study patterns of infection and effects of novel oHSV derivatives. Aim 3: To provide expert neuropathology, immunopathology, and molecular analysis of glioblastoma tissues and models (all Projects) including novel digital pathology deep-learning algorithms and multiplex immunofluorescence. In summary, the Core services will be essential to all Projects and will promote and prioritize collaboration to develop more effective oncolytic viral therapies for GBM and other cancers.